ATE397603T1 - Herstellungsverfahren von kristallinem losartan- kaliumsalz - Google Patents

Herstellungsverfahren von kristallinem losartan- kaliumsalz

Info

Publication number
ATE397603T1
ATE397603T1 AT04027598T AT04027598T ATE397603T1 AT E397603 T1 ATE397603 T1 AT E397603T1 AT 04027598 T AT04027598 T AT 04027598T AT 04027598 T AT04027598 T AT 04027598T AT E397603 T1 ATE397603 T1 AT E397603T1
Authority
AT
Austria
Prior art keywords
losartan potassium
production process
potassium salt
crystalline losartan
crystalline
Prior art date
Application number
AT04027598T
Other languages
English (en)
Inventor
Gabriele Razetti
Domenico Magrone
Mauro Ercoli
Pietro Allegrini
Graziano Castaldi
Original Assignee
Dipharma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dipharma Spa filed Critical Dipharma Spa
Application granted granted Critical
Publication of ATE397603T1 publication Critical patent/ATE397603T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04027598T 2003-12-16 2004-11-19 Herstellungsverfahren von kristallinem losartan- kaliumsalz ATE397603T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002472A ITMI20032472A1 (it) 2003-12-16 2003-12-16 Procedimento per la preparazione di losartan potassio cristallino

Publications (1)

Publication Number Publication Date
ATE397603T1 true ATE397603T1 (de) 2008-06-15

Family

ID=34509471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04027598T ATE397603T1 (de) 2003-12-16 2004-11-19 Herstellungsverfahren von kristallinem losartan- kaliumsalz

Country Status (7)

Country Link
US (1) US20050131040A1 (de)
EP (1) EP1544198B1 (de)
JP (1) JP2005179355A (de)
AT (1) ATE397603T1 (de)
DE (1) DE602004014237D1 (de)
ES (1) ES2306949T3 (de)
IT (1) ITMI20032472A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2179067A1 (en) * 1993-12-23 1995-06-29 Gordon Creston Campbell, Jr. Polymorphs of losartan and the process for the preparation of form ii of losartan
CZ291672B6 (cs) * 1996-10-29 2003-04-16 Merck And Co., Inc. Způsob krystalizace draselné soli losartanu
SK722003A3 (en) * 2001-05-18 2003-12-02 Aurobindo Pharma Ltd Process for the crystallization of losartan potassium
MXPA04004657A (es) * 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
ATE487478T1 (de) * 2003-01-30 2010-11-15 Lek Pharmaceuticals Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren

Also Published As

Publication number Publication date
EP1544198A1 (de) 2005-06-22
EP1544198B1 (de) 2008-06-04
ES2306949T3 (es) 2008-11-16
DE602004014237D1 (de) 2008-07-17
ITMI20032472A1 (it) 2005-06-17
JP2005179355A (ja) 2005-07-07
US20050131040A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
NO20050542L (no) Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin
NO20043345L (no) Fremgangsmate for fremstilling av hydrokarboner
ATE500201T1 (de) Herstellungsverfahren für polyolefin- nanocomposites
DE602004013405D1 (de) Polymorphe formen von valsartan
NO20050144D0 (no) Fremgangsmate for a fremstille substituerte pyrimidiner
NO20053796D0 (no) Process for the production of particles
IS7755A (is) Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín
FR2846964B1 (fr) Procede de fabrication de 1,2-epoxy-3-chloropropane
DK1480491T3 (da) Tynd højttaler samt fremgangsmåde til fremstilling deraf
ATE501153T1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
MA28635B1 (fr) Methode de production de derives de 1, 4-diphenylazetidinone
NO20033408D0 (no) Fremgangsmåte for fremstilling av krystallinske nanopartikler
IL176326A0 (en) Process for the production of proteins
PL1829868T3 (pl) Sposób wytwarzania soli (4,5-dihydroizoksazol-3-ilo)tiokarboksyamidyny
DE60220554D1 (de) Mikrowelleninduzierter prozess zur herstellung von substituierten 4-vinylphenolen
IS8184A (is) Aðferð við framleiðslu á handhverfulega hreinu mírtasapíni
EE00773U1 (et) Meetod vaba estsitalopraam-aluse v?i selle soola tootmiseks
NO20034597L (no) Fremgangsmate for fremstilling av cantaxantin
ATE397603T1 (de) Herstellungsverfahren von kristallinem losartan- kaliumsalz
EP1698703A4 (de) Verfahren zur dipeptidherstellung
IS7477A (is) Aðferð við framleiðslu sýrusalts af gemifloxasíni
GB0312968D0 (en) Process for the production of olefins
PL372922A1 (en) Novel o-isopropylisourea salts and process for the production thereof
FI20030381A0 (fi) Menetelmä prosessin säätämiseksi
FI20021421A0 (fi) Valmistusmenetelmä

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties